1297 related articles for article (PubMed ID: 25220373)
21. Reciprocal feedback inhibition of the androgen receptor and PI3K as a novel therapy for castrate-sensitive and -resistant prostate cancer.
Qi W; Morales C; Cooke LS; Johnson B; Somer B; Mahadevan D
Oncotarget; 2015 Dec; 6(39):41976-87. PubMed ID: 26506516
[TBL] [Abstract][Full Text] [Related]
22. Autocrine IGF-I/insulin receptor axis compensates for inhibition of AKT in ER-positive breast cancer cells with resistance to estrogen deprivation.
Fox EM; Kuba MG; Miller TW; Davies BR; Arteaga CL
Breast Cancer Res; 2013; 15(4):R55. PubMed ID: 23844554
[TBL] [Abstract][Full Text] [Related]
23. 1,25-dihydroxyvitamin D(3) and PI3K/AKT inhibitors synergistically inhibit growth and induce senescence in prostate cancer cells.
Axanova LS; Chen YQ; McCoy T; Sui G; Cramer SD
Prostate; 2010 Nov; 70(15):1658-71. PubMed ID: 20583132
[TBL] [Abstract][Full Text] [Related]
24. Synergistic activity of the mTOR inhibitor ridaforolimus and the antiandrogen bicalutamide in prostate cancer models.
Squillace RM; Miller D; Wardwell SD; Wang F; Clackson T; Rivera VM
Int J Oncol; 2012 Aug; 41(2):425-32. PubMed ID: 22614157
[TBL] [Abstract][Full Text] [Related]
25. Combinatorial antitumor effect of HDAC and the PI3K-Akt-mTOR pathway inhibition in a Pten defecient model of prostate cancer.
Ellis L; Ku SY; Ramakrishnan S; Lasorsa E; Azabdaftari G; Godoy A; Pili R
Oncotarget; 2013 Dec; 4(12):2225-36. PubMed ID: 24163230
[TBL] [Abstract][Full Text] [Related]
26. Antitumor activity of pimasertib, a selective MEK 1/2 inhibitor, in combination with PI3K/mTOR inhibitors or with multi-targeted kinase inhibitors in pimasertib-resistant human lung and colorectal cancer cells.
Martinelli E; Troiani T; D'Aiuto E; Morgillo F; Vitagliano D; Capasso A; Costantino S; Ciuffreda LP; Merolla F; Vecchione L; De Vriendt V; Tejpar S; Nappi A; Sforza V; Martini G; Berrino L; De Palma R; Ciardiello F
Int J Cancer; 2013 Nov; 133(9):2089-101. PubMed ID: 23629727
[TBL] [Abstract][Full Text] [Related]
27. Liposome encapsulation of curcumin and resveratrol in combination reduces prostate cancer incidence in PTEN knockout mice.
Narayanan NK; Nargi D; Randolph C; Narayanan BA
Int J Cancer; 2009 Jul; 125(1):1-8. PubMed ID: 19326431
[TBL] [Abstract][Full Text] [Related]
28. Dual targeting of androgen receptor and mTORC1 by salinomycin in prostate cancer.
Mirkheshti N; Park S; Jiang S; Cropper J; Werner SL; Song CS; Chatterjee B
Oncotarget; 2016 Sep; 7(38):62240-62254. PubMed ID: 27557496
[TBL] [Abstract][Full Text] [Related]
29. Epidermal growth factor modulates prostate cancer cell invasiveness regulating urokinase-type plasminogen activator activity. EGF-receptor inhibition may prevent tumor cell dissemination.
Festuccia C; Angelucci A; Gravina GL; Biordi L; Millimaggi D; Muzi P; Vicentini C; Bologna M
Thromb Haemost; 2005 May; 93(5):964-75. PubMed ID: 15886816
[TBL] [Abstract][Full Text] [Related]
30. Anti-cancer efficacy of SREBP inhibitor, alone or in combination with docetaxel, in prostate cancer harboring p53 mutations.
Li X; Wu JB; Chung LW; Huang WC
Oncotarget; 2015 Dec; 6(38):41018-32. PubMed ID: 26512780
[TBL] [Abstract][Full Text] [Related]
31. Combined Inhibition of PI3Kβ and mTOR Inhibits Growth of PTEN-null Tumors.
Lynch JT; Polanska UM; Hancox U; Delpuech O; Maynard J; Trigwell C; Eberlein C; Lenaghan C; Polanski R; Avivar-Valderas A; Cumberbatch M; Klinowska T; Critchlow SE; Cruzalegui F; Barry ST
Mol Cancer Ther; 2018 Nov; 17(11):2309-2319. PubMed ID: 30097489
[TBL] [Abstract][Full Text] [Related]
32. Multi-drug loaded micelles delivering chemotherapy and targeted therapies directed against HSP90 and the PI3K/AKT/mTOR pathway in prostate cancer.
Le B; Powers GL; Tam YT; Schumacher N; Malinowski RL; Steinke L; Kwon G; Marker PC
PLoS One; 2017; 12(3):e0174658. PubMed ID: 28350865
[TBL] [Abstract][Full Text] [Related]
33. Preclinical pharmacology of AZD5363, an inhibitor of AKT: pharmacodynamics, antitumor activity, and correlation of monotherapy activity with genetic background.
Davies BR; Greenwood H; Dudley P; Crafter C; Yu DH; Zhang J; Li J; Gao B; Ji Q; Maynard J; Ricketts SA; Cross D; Cosulich S; Chresta CC; Page K; Yates J; Lane C; Watson R; Luke R; Ogilvie D; Pass M
Mol Cancer Ther; 2012 Apr; 11(4):873-87. PubMed ID: 22294718
[TBL] [Abstract][Full Text] [Related]
34. Modulation of hypoxia-inducible factor 1alpha expression by the epidermal growth factor/phosphatidylinositol 3-kinase/PTEN/AKT/FRAP pathway in human prostate cancer cells: implications for tumor angiogenesis and therapeutics.
Zhong H; Chiles K; Feldser D; Laughner E; Hanrahan C; Georgescu MM; Simons JW; Semenza GL
Cancer Res; 2000 Mar; 60(6):1541-5. PubMed ID: 10749120
[TBL] [Abstract][Full Text] [Related]
35. The activity of the androgen receptor variant AR-V7 is regulated by FOXO1 in a PTEN-PI3K-AKT-dependent way.
Mediwala SN; Sun H; Szafran AT; Hartig SM; Sonpavde G; Hayes TG; Thiagarajan P; Mancini MA; Marcelli M
Prostate; 2013 Feb; 73(3):267-77. PubMed ID: 22821817
[TBL] [Abstract][Full Text] [Related]
36. Patient-derived Hormone-naive Prostate Cancer Xenograft Models Reveal Growth Factor Receptor Bound Protein 10 as an Androgen Receptor-repressed Gene Driving the Development of Castration-resistant Prostate Cancer.
Hao J; Ci X; Xue H; Wu R; Dong X; Choi SYC; He H; Wang Y; Zhang F; Qu S; Zhang F; Haegert AM; Gout PW; Zoubeidi A; Collins C; Gleave ME; Lin D; Wang Y
Eur Urol; 2018 Jun; 73(6):949-960. PubMed ID: 29544736
[TBL] [Abstract][Full Text] [Related]
37. Akt down-modulation induces apoptosis of human prostate cancer cells and synergizes with EGFR tyrosine kinase inhibitors.
Festuccia C; Gravina GL; Muzi P; Millimaggi D; Dolo V; Vicentini C; Bologna M
Prostate; 2008 Jun; 68(9):965-74. PubMed ID: 18361408
[TBL] [Abstract][Full Text] [Related]
38. Aberrant Expression of ERG Promotes Resistance to Combined PI3K and AR Pathway Inhibition through Maintenance of AR Target Genes.
Mao N; Gao D; Hu W; Hieronymus H; Wang S; Lee YS; Lee C; Choi D; Gopalan A; Chen Y; Carver BS
Mol Cancer Ther; 2019 Sep; 18(9):1577-1586. PubMed ID: 31296553
[TBL] [Abstract][Full Text] [Related]
39. Synthetic Lethality in PTEN-Mutant Prostate Cancer Is Induced by Combinatorial PI3K/Akt and BCL-XL Inhibition.
Ren W; Joshi R; Mathew P
Mol Cancer Res; 2016 Dec; 14(12):1176-1181. PubMed ID: 27590631
[TBL] [Abstract][Full Text] [Related]
40. MP470, a novel receptor tyrosine kinase inhibitor, in combination with Erlotinib inhibits the HER family/PI3K/Akt pathway and tumor growth in prostate cancer.
Qi W; Cooke LS; Stejskal A; Riley C; Croce KD; Saldanha JW; Bearss D; Mahadevan D
BMC Cancer; 2009 May; 9():142. PubMed ID: 19432987
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
